financetom
Business
financetom
/
Business
/
Birkenstock beats profit estimates on strong full-price footwear sales
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Birkenstock beats profit estimates on strong full-price footwear sales
Aug 14, 2025 2:55 AM

(Reuters) -German sandal maker Birkenstock ( BIRK ) beat third-quarter profit expectations on Thursday, helped by strong full-price sales of its sandals and shoes, and said it was well placed to manage the impact of the 15% U.S. tariff on European imports.

The company's shares jumped 5% in premarket trading, after it also stuck to its margin forecast for the year despite a "significantly weaker" dollar.

Birkenstock ( BIRK ), whose suede leather closed-toe Boston clogs sell at $179.95 each online, has seen firm demand over the past several quarters as wealthy shoppers showed few signs of resistance to price increases.

Sales grew 16% in constant currency terms in the Americas during the quarter, after 20% growth in the previous three months.

Sustained demand and strong full-price sales have also boosted performance at high-end peers such as Ralph Lauren's Polo t-shirts and Hoka shoes from Deckers Outdoor, as shoppers prioritize sought-after and trendy products.

Birkenstock's ( BIRK ) gross profit margin for the quarter ended June 30 jumped 100 basis points to 60.5%.

The company had earlier said it expected to fully offset tariffs impact, helped by a low-single-digit price increase, as it sources and manufactures nearly all of its products in Europe.

It reported quarterly revenue of 635 million euros ($741.49 million), compared with analysts' average estimate of 636.74 million euros, according to data compiled by LSEG.

On an adjusted basis, it earned 62 euros per share, above the estimate of 60 euros.

Birkenstock ( BIRK ) maintained fiscal year 2025 revenue growth at the high-end of its forecast range of 15% to 17% in constant currency.

($1 = 0.8564 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ukraine's Zelenskiy to visit Sweden on Wednesday for defence talks
Ukraine's Zelenskiy to visit Sweden on Wednesday for defence talks
Oct 21, 2025
STOCKHOLM, Oct 22 (Reuters) - Ukrainian President Volodymyr Zelenskiy will visit Sweden on Wednesday to meet with Prime Minister Ulf Kristersson in the city of Linkoping where the two leaders visit a company, the Swedish government said in a statement. The prime minister and President Zelenskiy will hold a joint press conference to present news regarding ​​defence exports, the Swedish...
Russia's Orenburg plant restarts taking gas from Kazakhstan field, energy minister says
Russia's Orenburg plant restarts taking gas from Kazakhstan field, energy minister says
Oct 21, 2025
Oct 22 (Reuters) - Russia's Orenburg gas plant has restarted receiving natural gas from Kazakhstan's Karachaganak field, Kazakhstan's energy minister said on Wednesday. ...
Trump administration plans new probe into global drug pricing, FT reports
Trump administration plans new probe into global drug pricing, FT reports
Oct 21, 2025
(Reuters) -President Donald Trump's administration is preparing a new probe into drug pricing practices among U.S. trading partners, a move that would lay the ground for fresh tariffs, the Financial Times reported on Wednesday, citing sources familiar with the matter.  Reuters could not immediately verify the report.  The imminent investigation would consider whether U.S. trading partners are underpaying for drugs,...
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
Oct 21, 2025
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults Ipsen to acquire all issued and outstanding shares of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved